secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001023024-24-000070
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma to acquire Alimera Sciences for $5.50/share + CVR, funded by $280M debt
--------------------------------------------------------------------------------

- Deal consideration: $5.50 cash plus one CVR per Alimera share; adds ~$105M in branded revenue to ANI's rare disease segment.
- CVR pays up to $0.25 per milestone: $0.25 if 2026 net revenue > $140M, $0.25 if 2027 net revenue > $160M.
- Financing: $280M committed debt from JPMorgan and Blackstone; deal expected to close by Dec 21, 2024.
- Accretion: high single to low double digit adj. non-GAAP EPS accretion in 2025; $35-38M adj. EBITDA incl. $10M cost synergies.
- Caligan Partners (~32.1% holder) agreed to vote in favor; termination fee $10.4M under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/0001023024-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/ani-20240621.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer